Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of Jentadueto® (linagliptin plus metformin).

Author: ScheenAndré J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Linagliptin, a DPP-4 inhibitor, offers a new option for combined therapy with metformin in type 2 diabetes. It shares a similar pharmacodynamic profile with other gliptins but has a unique pharmacokinetic profile characterized by negligible renal excretion.
Paper Details　
Original Abstract of the Article :
Metformin is the first-choice drug in the management of type 2 diabetes. However, most patients require a combined therapy to reach and/or maintain targets of glucose control. Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for combined therapy with metformin. Linagliptin shares a simila...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14740338.2013.771631

データ提供：米国国立医学図書館（NLM）

Jentadueto® (Linagliptin Plus Metformin): A New Combination for Type 2 Diabetes Management

This research explores the efficacy and safety of [Jentadueto®], a combination therapy consisting of [linagliptin] and [metformin], for the management of [type 2 diabetes]. The study highlights the importance of [combined therapy] in achieving and maintaining [glucose control] in patients with type 2 diabetes. The authors discuss the unique properties of [linagliptin], a [dipeptidyl peptidase-4 (DPP-4) inhibitor], which shares similar pharmacodynamic properties with other gliptins but has a distinct pharmacokinetic profile with [negligible renal excretion].

Expanding Treatment Options for Type 2 Diabetes

This research introduces Jentadueto® as a new combination therapy option for type 2 diabetes. The combination of linagliptin and metformin offers a potential advantage for patients who require [combined therapy] to achieve their glycemic goals.

Managing Type 2 Diabetes: A Multifaceted Approach

This research underscores the importance of a multifaceted approach to managing type 2 diabetes. It highlights the role of [combined therapy] in achieving and maintaining optimal glucose control. By considering the individual needs of each patient, healthcare providers can tailor treatment plans that effectively manage this chronic condition.

Dr.Camel's Conclusion

The desert of type 2 diabetes can be a challenging landscape to navigate. Jentadueto® offers a new pathway for managing this chronic condition, providing a potentially effective combination therapy for achieving and maintaining optimal glucose control. It's important to remember that every patient's journey is unique, and that working closely with your doctor is key to finding the best treatment for your specific needs.

Date :
  1. Date Completed 2013-10-31
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

23421949

DOI: Digital Object Identifier

10.1517/14740338.2013.771631

Related Literature

Article Analysis
・Side Effects of linagliptin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.